Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
- PMID: 14975064
- PMCID: PMC2147656
- DOI: 10.1186/1475-2883-2-S1-S7
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
Abstract
Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan(R) (ivermectin, Merck, Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance system required of all onchocerciasis mass treatment programs, 65 were cases of 'Probable' or 'Possible' Loa loa Encephalopathy temporally Related to treatment with Mectizan(R) (PLERM).A retrospective analysis of these 65 PLERM cases revealed that 97% were from southern Cameroon, 85% were male and 93% were being treated with ivermectin for the first time. The mean time to onset of symptoms was 1.7 days (95% CI: 1.3, 2.2) but the mean time to receiving medical attention after the onset of symptoms was 2.0 days (95% CI: 1.5, 2.6). Hospitalization was reported in 53 cases with a mean duration of 27.5 days (95% CI: 13.3, 41.6, n = 35). Clinical outcome was reported in 34 cases: 64.7% recovered fully, 11.8% had partial neurologic deficit and 23.5% died. For the 32 cases where quantitative L. loa data were reported, the arithmetic means with 95% confidence intervals were for 1) peripheral blood: pre-treatment - 164,250 mf/ml (79,537, 248,963; n = 4); post-treatment within 1 month - 3926 mf/ml (2,128, 5,725; n = 21) and within 5 to 6 months - 7800 mf/ml (3417, 12,183; n = 7); and for 2) cerebrospinal fluid: 32 mf/ml (7, 37; n = 10) within 1 month post-treatment.Pending further research on practical methods to exclude individuals with high intensity L. loa infection from onchocerciasis mass treatment programs, more emphasis should be placed on surveillance and monitoring to ensure early recognition, referral and management of SAEs, during the first 2 years when majority of the population is presumably naïve to ivermectin.
Figures


Similar articles
-
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.Filaria J. 2003 Oct 24;2 Suppl 1(Suppl 1):S3. doi: 10.1186/1475-2883-2-S1-S3. Filaria J. 2003. PMID: 14975060 Free PMC article.
-
Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.Filaria J. 2003 Oct 24;2 Suppl 1(Suppl 1):S2. doi: 10.1186/1475-2883-2-S1-S2. Filaria J. 2003. PMID: 14975059 Free PMC article.
-
Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.Trop Med Int Health. 2003 Sep;8(9):820-31. doi: 10.1046/j.1365-3156.2003.01091.x. Trop Med Int Health. 2003. PMID: 12950668
-
Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection.Ann Trop Med Parasitol. 1997 Sep;91(6):573-89. doi: 10.1080/00034989760671. Ann Trop Med Parasitol. 1997. PMID: 9425360 Review.
-
Control of onchocerciasis.Adv Parasitol. 2006;61:349-94. doi: 10.1016/S0065-308X(05)61009-3. Adv Parasitol. 2006. PMID: 16735169 Review.
Cited by
-
Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia.PLoS Negl Trop Dis. 2011 Aug;5(8):e1299. doi: 10.1371/journal.pntd.0001299. Epub 2011 Aug 30. PLoS Negl Trop Dis. 2011. PMID: 21912716 Free PMC article.
-
Apology and Unintended Harm in Global Health.Health Hum Rights. 2019 Jun;21(1):19-32. Health Hum Rights. 2019. PMID: 31239611 Free PMC article.
-
Situation analysis of parasitological and entomological indices of onchocerciasis transmission in three drainage basins of the rain forest of South West Cameroon after a decade of ivermectin treatment.Parasit Vectors. 2015 Apr 2;8:202. doi: 10.1186/s13071-015-0817-2. Parasit Vectors. 2015. PMID: 25886166 Free PMC article.
-
Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19.Am J Trop Med Hyg. 2023 Jul 17;109(3):650-655. doi: 10.4269/ajtmh.23-0121. Print 2023 Sep 6. Am J Trop Med Hyg. 2023. PMID: 37678804 Free PMC article.
-
Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa-endemic areas.Clin Infect Dis. 2015 Jan 1;60(1):55-63. doi: 10.1093/cid/ciu723. Epub 2014 Sep 18. Clin Infect Dis. 2015. PMID: 25234520 Free PMC article.
References
-
- Goa KL, McTavish D, Clissold SP. Ivermectin: a review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991;42:640–658. - PubMed
-
- World Health Organization Onchocerciasis and its control: report of a WHO Expert Committee on Onchocerciasis Control. Technical Report Series No. 852. Geneva World Health Organization. 1995. - PubMed
-
- Foege WH. 10 years of Mectizan®. Ann Trop Med Parasitol. 1998;92:S7–S10. - PubMed
-
- Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimens of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol. 1985;79:63–78. - PubMed
LinkOut - more resources
Full Text Sources
Medical